Kailera Therapeutics reported a net loss of $95.7 million for the third quarter 2026 as it increased spending to advance its obesity therapeutic candidates. The clinical-stage company remains pre-revenue, focusing investment on its GLP-1-based portfolio, backed by a substantial cash position of $1.04 billion providing runway through mid-2028.
Key Highlights
- Research and development expenses surged to $84.7 million from $27.0 million in the prior-year period, driven by clinical trial and manufacturing ramp-ups.
- The company completed an End-of-Phase 2 meeting with the FDA for ribupatide oral, with global Phase 3 trials expected to initiate in the first half of 2027.
- Both the Phase 3 KaiNETIC program for injectable ribupatide and the global Phase 2 trial for safiglipron are now fully enrolled, with data anticipated in mid-2027 and mid-2028.